{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-096799","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.361366+00:00","generated_at":"2026-05-30T02:02:58.032360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Longeveron reports Q3 2024 revenue up 177% YoY to $1.8M; HLHS trial enrollment >80%","bullets":["Revenue for nine months ended Sept 30, 2024: $1.8M, up 177% YoY from $0.6M.","Net loss narrowed to $11.9M for nine months 2024 from $15.3M in 2023, a 23% improvement.","Cash and equivalents $22.8M; expects to fund operations through Q4 2025.","Phase 2b HLHS trial ELPIS II >80% enrolled; FDA confirmed pivotal trial acceptable for BLA if positive.","Phase 2a Alzheimer's data (CLEAR MIND) presented at AAIC and CTAD24."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-096799","json":"https://secwatch.observer/filing/0001213900-24-096799.json","markdown":"https://secwatch.observer/filing/0001213900-24-096799.md","text":"https://secwatch.observer/filing/0001213900-24-096799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/0001213900-24-096799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/ea0220665-8k_longe.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:02:58.032360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}